Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

This study tests whether donafenib — a targeted therapy that blocks signals that help tumors grow — can prevent liver cancer (hepatocellular carcinoma) from returning after surgery. It enrolls patients who were successfully operated on but have features that suggest a higher risk of relapse. **You may be eligible if...** - You had surgery to fully remove liver cancer within the past 4 weeks - Your tumor characteristics suggest a higher risk of the cancer coming back - You have not had anti-cancer drug treatment before surgery (certain exceptions apply) **You may NOT be eligible if...** - Your liver cancer has spread to other organs - Your liver function is too poor to safely tolerate the drug - You have active hepatitis B with high viral levels not controlled by antiviral therapy Talk to your doctor to see if this trial is right for you.